CAR T Cell Manufacturing: One Patient, One Unbroken Record
Keep chain of identity unbroken from apheresis to infusion, link vector lots to patient batches and decide release on complete evidence.
In Short
- Two identifiers on autologous labels.
- Link vector lots to each batch.
- People decide release.
The Blood and Tissue Guide
Every unit identified. Every decision reviewed.
- Which rules reach your unit
- Receive, identify, quarantine
- Process, test, review
We ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Blood and Tissue Guide
Every unit identified. Every decision reviewed.
CAR T cell products are genetically modified T cells, usually made for one patient from that patient's own cells. FDA's final guidance Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products (January 2024) sets out chemistry, manufacturing and control expectations. It points to 21 CFR Part 1271 subpart D for documenting labelling and tracking from collection to administration. The guidance is nonbinding; licensing requirements in 21 CFR 600-610 were not opened for this review. This guide summarises the sources named here; it is orientation, not legal advice. Sources checked 5 Oct 2026.
Chain of identity from collection to infusion
The guidance states that labelling and tracking of material from collection through administration must be documented, citing 21 CFR Part 1271 subpart D. For autologous products FDA recommends at least two unique identifiers on labels, with label checks built into the batch record before each processing step, and two independent patient and label checks at the bedside.
Worked Example: Chain of Identity for Patient Lot CT-0091
- CollectionApheresis bag labelled with two identifiersCollection site
- ReceiptBoth identifiers checked against the orderReceiving technician
- Each stepLabel check recorded in batch recordOperator
- ReleaseResults reviewed; release decidedQuality unit
- InfusionTwo independent patient and label checksClinical site
More on chain of identity from collection to infusion
Design your record so every handoff, from apheresis to final infusion bag, shows who checked which identifiers and when.
Starting Material Characterisation
Leukapheresis material varies between patients. The guidance notes that characterising cell populations such as CD4+ and CD8+ T cells, NK cells, monocytes and B cells may inform manufacturing, because these characteristics can influence selection, expansion and final quality.
More on starting Material Characterisation
Record what you measured at receipt, the acceptance criteria and any decision to proceed outside them, with the responsible person's approval. That history matters when results downstream are unexpected.
Vector and Transduction Controls
The guidance discusses controls on the vector used to introduce the CAR, and on the transduced product, including vector copy number, which should remain within target specifications. Keep vector lot identity and test results linked to every patient batch made with that lot.
Vector lot trace (illustrative)
| Vector lot | Patient batches | If a result changes |
|---|---|---|
| VL-22 | CT-0088, CT-0091 | Quality assesses both batches |
| VL-23 | CT-0094 | No action |
| VL-24 | Not yet used | Hold pending review |
- VL-22
- Patient batches
- CT-0088, CT-0091
- If a result changes
- Quality assesses both batches
- VL-23
- Patient batches
- CT-0094
- If a result changes
- No action
- VL-24
- Patient batches
- Not yet used
- If a result changes
- Hold pending review
More on vector and Transduction Controls
If a vector lot result changes after use, you need to find every affected batch quickly, which depends on genealogy recorded during manufacture rather than reconstructed later.
Potency and Release Testing
FDA notes that strength is the equivalent of potency, defined at 21 CFR 600.3(s), and expects testing that shows the product meets standards of identity, quality, safety, purity and potency. Release often happens under tight timelines with some results pending.
More on potency and Release Testing
Define in advance which results must be complete before release and which may follow, and who decides. Record each release decision with the evidence the decision-maker saw.
Changes during development
The guidance discusses how manufacturing changes, such as a different potency assay, may need comparability assessment. Keep changes under formal change control with the reason, risk assessment, data and approval, and link them to the batches made before and after.
More on changes during development
A clear change history lets reviewers understand why the process today differs from the one used in early clinical lots, without relying on memory.
Questions
What does FDA recommend for autologous labelling?
At least two unique identifiers, label checks in the batch record before each processing step, and two independent patient and label checks at the bedside.
Is the January 2024 CAR T guidance binding?
No. It is final guidance reflecting FDA's current thinking. Binding requirements come from the statute and regulations it cites, such as Part 1271 subpart D.
Why link vector lots to patient batches?
Vector copy number and other vector results affect product quality. Linked genealogy lets you find every batch made with a lot if a result changes.
Who decides release when some results are pending?
Your quality unit decides under procedures defined in advance. Software can show which results are complete; it should not make the release decision.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
Keep reading
21 CFR 1271 Readiness for Tissue and Cell Establishments
AABB Blood Bank Standards and 21 CFR 606 Readiness Guide
Cord Blood Bank cGMP Readiness: 1271, BLA and FACT-NetCord
Donor Eligibility, Lookback and Deviation Readiness
EU Tissues and Cells Directive 2004/23/EC and the SoHO Regulation
FACT-JACIE Accreditation Readiness for Cell Therapy